Gastric cancer remains a major unmet clinical problem with over 1 million new cases
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …

Simple Summary Gastric cancer is the fifth most common tumor worldwide. In the past
couple of decades, there have been many advancements toward earlier detection and better …

Purpose There is currently no standard treatment strategy for patients with advanced
metastatic gastric cancer experiencing progression after two or more lines of chemotherapy …

Purpose Patients with metastatic gastric cancer (mGC) who do not respond to or who
experience progression with second-line chemotherapy have no treatment options that …

Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced
gastric adenocarcinoma. Patients and Methods We conducted an international (Australia …

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in cancer
angiogenesis. In this study, a series of novel furo [2, 3-d] pyrimidine and thieno [2, 3-d] …

PURPOSE To evaluate the safety, pharmacokinetics, and preliminary activity of
bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal …

Purpose: To observe the mechanism of the effects of Apatinib on the proliferation and
apoptosis of human gastric cancer (HGC-27) cells via the phosphatidylinositol 3-kinase …

Despite advances in the treatment of gastric cancer, it remains the world's second highest
cause of cancer death. As gastric cancer is often diagnosed at an advanced stage, systemic …

Background: Docetaxel is widely used as a chemotherapeutic agent for gastric cancer
treatment. A combined regimen with sunitinib demonstrated a synergistic antitumour effect in …